Kazuhiko Kakimi (Kazuhiro Kakimi)

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 15

Top Topics

Monoclonal Antibody

Randomized Controlled Trial

Top Venues

Journal for immunotherapy of cancer

Cell death discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuyoshi Sato, Hiroharu Yamashita, Yukari Kobayashi, Koji Nagaoka, Tetsuro Hisayoshi, Takuya Kawahara, Akihiro Kuroda, Noriyuki Saito, Ryohei Iwata, Yasuhiro Okumura, Koichi Yagi, Susumu Aiko, Sachiyo Nomura, Kazuhiko Kakimi, Yasuyuki Seto
Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer. International journal of molecular sciences 24 (23) (2023)
Kaoru Fujikawa, Takuro Saito, Koji Kurose, Takashi Kojima, Takeru Funakoshi, Eiichi Sato, Kazuhiko Kakimi, Shinsuke Iida, Yuichiro Doki, Mikio Oka, Ryuzo Ueda, Hisashi Wada
Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors. PloS one 18 (9) (2023)
Tsukasa Masuda, Nobuyuki Tanaka, Kimiharu Takamatsu, Kyohei Hakozaki, Ryohei Takahashi, Tadatsugu Anno, Ryohei Kufukihara, Kazunori Shojo, Shuji Mikami, Toshiaki Shinojima, Kazuhiko Kakimi, Tatsuhiko Tsunoda, Eriko Aimono, Hiroshi Nishihara, Ryuichi Mizuno, Mototsugu Oya
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. Journal for immunotherapy of cancer 10 (3) (2022)
Changbo Sun, Koji Nagaoka, Yukari Kobayashi, Kazuhiro Maejima, Hidewaki Nakagawa, Jun Nakajima, Kazuhiko Kakimi
Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors. International journal of cancer (2022)
Hirotaka Kawanabe-Matsuda, Kazuyoshi Takeda, Marie Nakamura, Seiya Makino, Takahiro Karasaki, Kazuhiko Kakimi, Megumi Nishimukai, Tatsukuni Ohno, Jumpei Omi, Kuniyuki Kano, Akiharu Uwamizu, Hideo Yagita, Ivo Gomperts Boneca, Gérard Eberl, Junken Aoki, Mark J Smyth, Ko Okumura
Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy. Cancer discovery 12 (5) (2022)
Mikako Nishida, Nahoko Yamashita, Taisaku Ogawa, Keita Koseki, Eiji Warabi, Tomoyuki Ohue, Masaaki Komatsu, Hirokazu Matsushita, Kazuhiko Kakimi, Eiryo Kawakami, Katsuyuki Shiroguchi, Heiichiro Udono
Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes. Journal for immunotherapy of cancer 9 (9) (2022)
Taisuke Ishii, Imari Mimura, Koji Nagaoka, Akihiro Naito, Takehito Sugasawa, Ryohei Kuroda, Daisuke Yamada, Yasuharu Kanki, Haruki Kume, Tetsuo Ushiku, Kazuhiko Kakimi, Tetsuhiro Tanaka, Masaomi Nangaku
Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. Cell death discovery 8 (1) (2022)
Koji Nagaoka, Masataka Shirai, Kiyomi Taniguchi, Akihiro Hosoi, Changbo Sun, Yukari Kobayashi, Kazuhiro Maejima, Masashi Fujita, Hidewaki Nakagawa, Sachiyo Nomura, Kazuhiko Kakimi
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. Journal for immunotherapy of cancer 8 (2) (2021)
Kazuhiko Kakimi, Hirokazu Matsushita, Keita Masuzawa, Takahiro Karasaki, Yukari Kobayashi, Koji Nagaoka, Akihiro Hosoi, Shinnosuke Ikemura, Kentaro Kitano, Ichiro Kawada, Tadashi Manabe, Tomohiro Takehara, Toshiaki Ebisudani, Kazuhiro Nagayama, Yukio Nakamura, Ryuji Suzuki, Hiroyuki Yasuda, Masaaki Sato, Kenzo Soejima, Jun Nakajima
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer 8 (2) (2021)
Yoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato, Takuma Irie, Atsuo Sai, Kota Itahashi, Shogo Kumagai, Yasuko Tada, Yosuke Togashi, Syohei Koyama, Esra A Akbay, Takahiro Karasaki, Keisuke Kataoka, Soichiro Funaki, Yasushi Shintani, Izumi Nagatomo, Hiroshi Kida, Genichiro Ishii, Tomohiro Miyoshi, Keiju Aokage, Kazuhiko Kakimi, Seishi Ogawa, Meinoshin Okumura, Masatoshi Eto, Atsushi Kumanogoh, Masahiro Tsuboi, Hiroyoshi Nishikawa
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science immunology 6 (65) (2021)
Yuka Maeda, Hisashi Wada, Daisuke Sugiyama, Takuro Saito, Takuma Irie, Kota Itahashi, Kodai Minoura, Susumu Suzuki, Takashi Kojima, Kazuhiko Kakimi, Jun Nakajima, Takeru Funakoshi, Shinsuke Iida, Mikio Oka, Teppei Shimamura, Toshihiko Doi, Yuichiro Doki, Eiichi Nakayama, Ryuzo Ueda, Hiroyoshi Nishikawa
Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature communications 12 (1) (2021)
Koji Nagaoka, Changbo Sun, Yukari Kobayashi, Takayuki Kanaseki, Serina Tokita, Toshihiro Komatsu, Kazuhiro Maejima, Junichiro Futami, Sachiyo Nomura, Keiko Udaka, Hidewaki Nakagawa, Toshihiko Torigoe, Kazuhiko Kakimi
Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy. Cancers 14 (1) (2021)
Yukari Kobayashi, Yoshihiro Kushihara, Noriyuki Saito, Shigeo Yamaguchi, Kazuhiko Kakimi
A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions. Cancer science 111 (11) (2020)
Masami Yamamoto, Sachiyo Nomura, Akihiro Hosoi, Koji Nagaoka, Tamaki Iino, Tomohiko Yasuda, Tomoko Saito, Hirokazu Matsushita, Eiji Uchida, Yasuyuki Seto, James R Goldenring, Kazuhiko Kakimi, Masae Tatematsu, Tetsuya Tsukamoto
Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer science 109 (5) (2018)
Kazuhiko Kakimi, Takahiro Karasaki, Hirokazu Matsushita, Tomoharu Sugie
Advances in personalized cancer immunotherapy. Breast cancer (Tokyo, Japan) 24 (1) (2016)